KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EBT: 2017-2024

Historic EBT for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Dec 2024 value amounting to $7.4 million.

  • Aurinia Pharmaceuticals' EBT rose 115.86% to $32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.6 million, marking a year-over-year increase of 495.41%. This contributed to the annual value of $7.4 million for FY2024, which is 109.61% up from last year.
  • According to the latest figures from FY2024, Aurinia Pharmaceuticals' EBT is $7.4 million, which was up 109.61% from -$77.5 million recorded in FY2023.
  • Over the past 5 years, Aurinia Pharmaceuticals' EBT peaked at $7.4 million during FY2024, and registered a low of -$180.2 million during FY2021.
  • Over the past 3 years, Aurinia Pharmaceuticals' median EBT value was -$77.5 million (recorded in 2023), while the average stood at -$58.8 million.
  • Its EBT has fluctuated over the past 5 years, first crashed by 75.34% in 2021, then spiked by 109.61% in 2024.
  • Yearly analysis of 5 years shows Aurinia Pharmaceuticals' EBT stood at -$102.8 million in 2020, then plummeted by 75.34% to -$180.2 million in 2021, then soared by 40.98% to -$106.4 million in 2022, then increased by 27.16% to -$77.5 million in 2023, then spiked by 109.61% to $7.4 million in 2024.